Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the transaction, the vice president directly owned 74,424 shares in the company, valued at $5,617,523.52. The trade was a 0.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Monday, July 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $81.84, for a total transaction of $40,920.00.
• On Friday, June 12th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.03, for a total transaction of $41,015.00.

ANI Pharmaceuticals Trading Up 2.4%

Shares of NASDAQ ANIP opened at $76.54 on Friday. The company’s fifty day moving average is $80.82 and its 200-day moving average is $79.03. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of 16.50 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a twelve month low of $70.15 and a twelve month high of $99.50. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. During the same quarter in the prior year, the company earned $1.80 EPS. The firm’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV acquired a new position in ANI Pharmaceuticals during the first quarter worth $28,000. Advisors Asset Management Inc. acquired a new stake in ANI Pharmaceuticals in the 1st quarter valued at $28,000. Hantz Financial Services Inc. lifted its position in ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. bought a new stake in ANI Pharmaceuticals during the 4th quarter worth about $48,000. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals during the 2nd quarter worth about $50,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. Guggenheim dropped their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday. Canaccord Genuity Group cut their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Finally, Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.